Nuformix PLC
LSE:NFX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.07
0.485
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Nuformix PLC
LSE:NFX
|
4.4m GBP |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
977.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
545B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
279.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.2B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.9B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Nuformix PLC
Glance View
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.